TMDX: Sustained 86% CAGR, profitability, and four-pronged growth strategy drive market expansion
Achieved 86% CAGR since FY22, reaching profitability and scaling a multi-organ platform with three FDA-approved products. Four growth initiatives target heart, lung, and kidney markets, EU expansion, and next-gen technology, nearly doubling the addressable market.Original document: TransMedics Grou…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.